# A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma

> **NCT07741617** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School** · enrollment: 54 (estimated)

## Conditions studied

- Urologic Neoplasms

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab in combination with Lenvatinib

## Key facts

- **NCT ID:** NCT07741617
- **Lead sponsor:** The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08-15
- **Primary completion:** 2028-08-15
- **Final completion:** 2030-08-15
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-08-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07741617

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07741617, "A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07741617. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*